ASH 2022 | InformCLL registry analysis: ibrutinib vs chemoimmunotherapy for the first-line treatment of CLL/SLL
Nilanjan Ghosh, MD, PhD, Levine Cancer Institute, Charlotte, NC, presents results from a real-world analysis using data from the InformCLL registry (NCT02582879) that aimed to compare outcomes after first-line ibrutinib versus chemoimmunotherapy (CIT) in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Following propensity score matching, ibrutinib was associated with a longer time to next treatment (TTNT), with sustained benefit after four years of follow-up. In addition, ibrutinib was associated with a decreased rate of serious adverse events and treatment discontinuation. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Genmab: Consultancy; Loxo Oncology: Consultancy; Novartis: Consultancy; Roche/Genentech: Consultancy, Research Funding; Karyopharm: Consultancy; Incyte: Consultancy; Beigene: Consultancy; Gilead: Consultancy, Research Funding, Speakers Bureau; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Pharmacyclics: Consultancy, Speakers Bureau; AstraZeneca: Consultancy, Speakers Bureau; TG Therapeautics: Consultancy, Research Funding; Seagen: Consultancy; Levine Cancer Institute: Current Employment, Honoraria, Research Funding; Adaptive Biotech: Consultancy; ADC Therapeautics: Consultancy; Epizyme: Speakers Bureau; Morphosys: Research Funding; AbbVie: Research Funding.
